Trials / Completed
CompletedNCT05384977
Mass Balance Study of NV-5138 in Healthy Male Subjects
An Open-label, Single Dose, Mass Balance Study to Assess the Disposition of [14C]-NV-5138 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the mass balance and routes of excretion of total radioactivity after a single oral dose of 1600 mg \[14C\]-NV-5138.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-NV-5138 | Single dose, given as oral solution, 1600 mg |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2021-12-09
- Completion
- 2021-12-09
- First posted
- 2022-05-23
- Last updated
- 2022-05-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05384977. Inclusion in this directory is not an endorsement.